Dr. Abdulla Al Mandous Named UAE’s Official Candidate for WMO Presidency
1.2.2023 16:14:00 EET | Business Wire | Press release
The UAE Ministry of Foreign Affairs and International Cooperation (MoFAIC) has named His Excellency Dr. Abdulla Al Mandous, the Director General of the National Center of Meteorology (NCM), as the UAE’s official candidate for the Presidency of the World Meteorological Organization (WMO). Dr. Al Mandous is currently serving as the UAE's Permanent Representative to WMO and President of WMO’s Regional Association II (Asia).
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230201005580/en/
His Excellency Dr. Abdulla Al Mandous, the Director General of the National Center of Meteorology (NCM) (Photo: AETOSWire)
With over 30 years of experience in meteorology and climate science, Dr. Al Mandous is well-known to the global weather and climate community and was appointed by WMO as a member of its Expert Team on Weather Modification in April 2021.
Dr. Abdulla Al Mandous said: “The UAE's official announcement in support of my WMO presidency candidacy reiterates the importance the country attaches to meteorology, weather, climate and related water and environmental issues. It is a top priority for the UAE to ensure that it pools its expertise and human capital with other National and Global Organizations to accelerate the development of comprehensive early warning systems to protect lives from the impacts of natural disasters.”
Shaima Mohammed Al Ali, Director of International Organisations at MoFAIC, said: “At a time when the world is facing multiple challenges due to climate change and the upcoming UAE’s Presidentship of COP 28 during November 2023, the candidacy of Dr. Abdulla Al Mandous for WMO presidency is a timely decision by the UAE given his experience and track record in leading several national, regional and international meteorological entities. He is the right choice to lead WMO into the future to ensure that the organization continues to play a vital role in supporting the sustainable development of nations around the world.”
As the UAE’s official representative for the WMO Presidency, Dr. Al Mandous will seek to accelerate an internationally coordinated action to achieve UN Secretary-General’s call to ensure that “every person on Earth is protected by Early Warning Systems in the next five years”. His five-pillar approach focuses on supporting the role of Regional Associations’ Presidents and Permanent Representatives, making ‘Early Warnings for All’ a reality, advancing the High-Resolution Climate Computing Research, recognizing WMO by the Global Society, and taking proactive steps in Water Security and Renewable Energy Research.
*Source: AETOSWire
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230201005580/en/
Contact information
Salam Shehady, 00971553584520
sshehady@apcoworldwide.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Zynyz ® (retifanlimab) for First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)30.1.2026 16:29:00 EET | Press release
Incyte (Nasdaq:INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) for the first-line treatment of adult patients with metastatic or with inoperable locally recurrent squamous cell carcinoma of the anal canal (SCAC). “Today’s positive CHMP opinion is an important step towards addressing the urgent need for new treatment options for patients in Europe with advanced SCAC, a disease which has seen limited innovation for decades,” said Lee Heeson, Executive Vice President and Head of Incyte International. “If approved, Zynyz in combination with platinum-based chemotherapy has the potential to become a new standard-of-care for patients living with this rare and difficult-to-treat cancer.” The positive CHMP opinion was based on data from the Phase 3 POD1UM-303/Inter
Mediawan to Acquire The North Road Company, Creating a New Global Independent Content Platform30.1.2026 14:32:00 EET | Press release
Mediawan, the leading independent European studio led by Pierre-Antoine Capton, co-founded by Capton, Xavier Niel and Matthieu Pigasse, today announced the signing of an agreement to acquire The North Road Company (“North Road”), the preeminent independent U.S.-based studio founded by Peter Chernin. The combination creates one of the world’s largest independent studios with major creative hubs in the five continents and capabilities spanning all genres, formats and audiences. Together, Mediawan and North Road will have a stronger ability to accelerate the development of powerful IP, foster fresh creative synergies through format adaptations and co-production opportunities, and deliver ever greater value to viewers, talent and partners worldwide. The acquisition brings together two of the most dynamic independent studios in the sector with world-class creative talent, premium IP, and the scale to deliver content at the highest level. In an industry undergoing significant consolidation,
BrightSign Powers Intelligent Signage Experiences at ISE 202630.1.2026 10:00:00 EET | Press release
With more industries embracing the power of visual storytelling, BrightSign, the provider of the most advanced, capable, and trusted digital media players and operating system, will showcase the latest developments in digital signage technology at ISE 2026 in Barcelona, Spain from February 3-6, 2026. BrightSign’s latest innovations come to life at booth #4S-150 through interactive real-world demos featuring retail, QSR, transportation, and corporate use cases. Visitors can test new AI-powered object detection capabilities of BrightSign players, allowing them to pick up an object and see the content on the screen respond immediately. Booth activations will be powered by BrightSign’s reliable platform including bsn.Control, BrightSignOS™, brightAuthor connected, and its global partner ecosystem. “In today’s immersive, personalized and visual world, the stakes have never been higher for powerful, secure, reliable, and intelligent digital signage,” said Steve Durkee, chief executive office
Candela Ushers in a New Era of Aesthetic Innovation at IMCAS Paris With the Launch of the Glacē™ System30.1.2026 09:30:00 EET | Press release
Candela, a global leader in energy-based aesthetic technologies, today announced the European launch of the Glacē™ System, a facial treatment platform that signals a bold new chapter for the company and the future of aesthetic medicine. In addition to the launch of the Glacē System, Candela will also showcase its Matrix system for radiofrequency-based skin renewal and its iconic Vbeam® Pro vascular treatment platform at IMCAS 2026. Both Matrix and VBeam Pro platforms are currently available in select EMEA markets and are expected to be comprehensively launched shortly, further strengthening Candela’s leadership in the energy-based device market. Unveiled at the IMCAS World Congress 2026, these launches underscore Candela’s continued commitment to delivering innovative, science-backed treatment solutions for high-demand patient needs. Candela leads the industry in clinical efficacy and safety, supported by one of the largest bodies of published clinical data backed by decades of clinica
Merz Therapeutics Appoints Dan Staner as President, Region Europe30.1.2026 09:00:00 EET | Press release
Merz Therapeutics today announced the appointment of Dan Staner as President, Region Europe, effective February 1, 2026. In this role, Dan will oversee the company’s European business and drive regional growth. Dan will report directly to Merz Therapeutics Chief Executive Officer, Stefan König, and will join the Therapeutics Executive Team. His appointment reflects the company’s continued commitment to strengthening its leadership capabilities and accelerating its growth strategy across key European markets. “Dan brings a strong track record of building and scaling biopharmaceutical businesses across Europe,” said Stefan König, CEO of Merz Therapeutics. “His deep commercial, strategic, and regional leadership experience will be instrumental in advancing our growth ambitions, expanding patient access to our therapies, and further strengthening our presence in Europe. We are very pleased to welcome Dan to Merz Therapeutics.” Throughout his career, Dan has held senior leadership roles i
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
